215 related articles for article (PubMed ID: 34741996)
1. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders.
Mirjalili SZ; Sabourian R; Sadeghalvad M; Rezaei N
Int Immunopharmacol; 2021 Dec; 101(Pt B):108305. PubMed ID: 34741996
[TBL] [Abstract][Full Text] [Related]
2. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
[TBL] [Abstract][Full Text] [Related]
3. [Biosimilars in rheumatology and other fields of medicine].
Milchert M; Fliciński J; Brzosko M
Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
[TBL] [Abstract][Full Text] [Related]
4. Expert perspectives on biosimilar monoclonal antibodies in breast cancer.
Cortés J; Curigliano G; Diéras V
Breast Cancer Res Treat; 2014 Apr; 144(2):233-9. PubMed ID: 24562824
[TBL] [Abstract][Full Text] [Related]
5. [Biosimilars in the European Union: current situation and challenges].
Wolff-Holz E; Weise M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of biosimilars in oncology.
Schellekens H; Smolen JS; Dicato M; Rifkin RM
Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
Gecse KB; Lakatos PL
Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
Calvo B; Zuñiga L
Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
[TBL] [Abstract][Full Text] [Related]
10. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.
Guillen E; Ekman N; Barry S; Weise M; Wolff-Holz E
Clin Pharmacol Ther; 2023 Jan; 113(1):108-123. PubMed ID: 36546547
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
[No Abstract] [Full Text] [Related]
13. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
16. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
[TBL] [Abstract][Full Text] [Related]
18. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States.
Cheng CA; Jiang AL; Liu YR; Chang LC
Clin Pharmacol Ther; 2023 Dec; 114(6):1274-1284. PubMed ID: 37634125
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
